EDGE
  • home.svg
    Home
  • news.svg
    All updates
  • news.svg
    EDGE Insights
  • list.svg
    Industries
  • db-search.svg
    Company Search
  • company-list.svg
    My Watchlists (Beta)
All Updates

All Updates

icon
Filter
Funding
Co-diagnostics secures USD 1.2 million from NIH
Precision Medicine
Jul 13, 2023
This week:
Funding
Matr Foods raises EUR 20 million in debt funding to build mycelium meat factory
Plant-based Meat
Today
Last week:
M&A
Platform Science to acquire Trimble's global transportation telematics business units
Truck Industry Tech
Yesterday
Funding
Whatfix raises USD 100 million in Series E funding to expand business
EdTech: Corporate Learning
Yesterday
Product updates
Sky Mavis launches cross-game onboarding solution
Web3 Ecosystem
Sep 14, 2024
Funding
Bicara Therapeutics raises USD 315 million in IPO; plans to develop lead candidate ficerafusp alfa
Precision Medicine
Sep 13, 2024
Partnerships
Massive Bio and Foundation Medicine partner to improve cancer clinical trial enrollment
Precision Medicine
Sep 13, 2024
Partnerships
Moffitt Cancer Center partners with AstraZeneca to advance oncology cell therapies
Cell & Gene Therapy
Sep 13, 2024
Product updates
Quandela launches European quantum computer in North America
Quantum Computing
Sep 13, 2024
Partnerships
IonQ achieves high qubit gate fidelity on barium development platform
Quantum Computing
Sep 13, 2024
Partnerships
Massive Bio and Foundation Medicine partner to improve cancer clinical trial enrollment
Clinical Trial Technology
Sep 13, 2024
Precision Medicine

Precision Medicine

View industry hub
Jul 13, 2023

Co-diagnostics secures USD 1.2 million from NIH

Funding

  • Molecular diagnostics company Co-Diagnostics, Inc. has received USD 1.2 million in funding from the National Institutes of Health (NIH) through the RADx Tech program. This brings the total funds raised by the company to USD 6.2 million.

  • The funds will be used to finalize the development of the company’s flu A/B, Covid-19, and RSV multiplex test and prepare for clinical trials on the Co-Dx PCR Home platform. The company also plans to submit the platform to the FDA and launch the Covid-19 test as its initial product.

  • Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets advanced diagnostic technologies. Its Co-Dx PCR Home platform utilizes nucleic acid detection and analysis to create tests for infectious diseases, including Covid-19. The company aims to make high-quality and affordable diagnostics more accessible globally. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.